PTC Therapeutics slides as Jefferies cuts to Hold, trims target to $76
PTC Therapeutics shares are lower as investors react to a recent Jefferies downgrade to Hold with a reduced price target of $76. The pullback also comes as the market looks ahead to the company’s next expected earnings report in late April to early May 2026.
1) What’s moving the stock
PTC Therapeutics (PTCT) is trading lower as selling pressure follows a recent analyst reset: Jefferies downgraded the stock to Hold and lowered its price target to $76 (from $91). (gurufocus.com)
2) Why this matters now
A downgrade can spark near-term de-risking, especially after a run-up, because it signals a more balanced risk/reward and can tighten incremental demand from rating-driven buyers. With PTCT now trading near the high-$60s, the new $76 target implies less upside than prior bulls had modeled, which can pressure momentum-oriented positioning. (gurufocus.com)
3) What to watch next
The next major catalyst is the company’s upcoming quarterly earnings release window. Several market calendars currently point to late April or early May 2026 (with some services listing April 23, 2026 after the close, and others listing May 5, 2026), so traders may stay cautious until the company confirms timing and updates guidance. (tipranks.com)